EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study

Takahiro Ito, Yasuyuki Kanno, Tsuyoshi Enokihara, Keiko Handa, Takahiro Yamamoto, Kiyoko Tanigawa, Yosuke Tsukinaga

Journal of Gerontology and Geriatrics · 23.07.2026 · 74 (3) · 23

DOI: 10.3390/jgg74030023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gerontology and Geriatrics, online erschienen am 23.07.2026. Verfasst von Takahiro Ito und 6 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to evaluate short-term outcomes and safety of elobixibat in home-care patients with chronic constipation (CC) and explore the changes in caregiver burden related to bowel management. This multicenter prospective observational study evaluated bowel movement status, defecation-related symptoms, and caregiver burden in home-care patients diagnosed with CC who had hard stools classified as Bristol Stool Form Scale (BSFS) type 1 or 2. Elobixibat was administered to home-care patients once a day for 4 weeks before a meal. The primary endpoint was the proportion of patients with normal stools at week 2 in patients who were able to excrete independently. Secondary endpoints included the proportion of patient with normal stools at week 4, stool consistency, stool frequency, defecation-related symptoms at weeks 2 and 4, caregiver burden at week 4, concomitant laxative use during the study period, and adverse events. Analyses were based on available data at each assessment time point. The proportion of patient with normal stools at week 2 in patients who could excrete independently was 53% (8/15; 95% CI, 30–75%). Weekly defecation frequency significantly increased at week 4 (n = 20, p = 0.02, without multiplicity adjustment) and was associated with potential improvements in defecation-related symptoms (straining, abdominal bloating) and patient satisfaction. The most common adverse event was mild diarrhea (17%), with no new safety signals observed over 4 weeks. The caregiver questionnaire, evaluated in a limited subset of seven respondents, showed preliminary descriptive changes in physical, psychological, and social burdens. This uncontrolled, exploratory observational study suggests that elobixibat was associated with improvements in defecation-related outcomes in home-care patients with CC. However, these findings should be interpreted with caution due to the small sample size and potential confounding from concomitant laxative use. Caregiver burden findings were descriptive and hypothesis-generating and require confirmation in larger, controlled studies.

Förderung

  • EA Pharma Co., Ltd.
  • Mochida Pharmaceutical Co., Ltd.

Zitieren

APA

Ito, T., Kanno, Y., Enokihara, T., Handa, K., Yamamoto, T., Tanigawa, K., & Tsukinaga, Y. (2026). Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study. Journal of Gerontology and Geriatrics, 74(3), 23. https://doi.org/10.3390/jgg74030023

Vancouver

Ito T, Kanno Y, Enokihara T, Handa K, Yamamoto T, Tanigawa K, et al. Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study. Journal of Gerontology and Geriatrics. 2026;74(3):23. doi:10.3390/jgg74030023

BibTeX
@article{Ito2026,
  author = {Ito, Takahiro and Kanno, Yasuyuki and Enokihara, Tsuyoshi and Handa, Keiko and Yamamoto, Takahiro and Tanigawa, Kiyoko and Tsukinaga, Yosuke},
  title = {Short-Term Outcomes of Elobixibat in Home-Care Patients with Chronic Constipation: A Multicenter, Prospective, Observational Study},
  journal = {Journal of Gerontology and Geriatrics},
  year = {2026},
  volume = {74},
  number = {3},
  pages = {23},
  doi = {10.3390/jgg74030023}
}
Kostenlos starten →